Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,801–8,900 of 15,747
Medical publishing during the COVID-19 pandemic: then and now
Becker, R. C., & Bode, C. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02422-6 · Cited by 6
Kang, B., Chu, H., Youn, B.-Y., & Leem, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i28.10053 · Cited by 8
Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report
Corica, B., Cacciani, A., Cangemi, R., Visentini, M., Recchia, F., Grillo, L. R., Vano, M., Sperduti, N., Cincione, A., Buoninfante, G., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.10.008 · Cited by 6
Janani, L., Phillips, R., Vogt, E. V., Liu, X., Waddington, C. S., & Cro, S. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae104 · Cited by 10
Keep, S., Stevenson-Leggett, P., Webb, I., Fones, A., Kirk, J., Britton, P., & Bickerton, E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297516 · Cited by 6
Baek, Y. J., Lee, Y.-J., Park, S. R., Kim, K. H., Beom, S., Lee, C., Shin, S. J., Rha, S. Y., Kim, S., Lee, K. H., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1541 · Cited by 6
Abue, M., Mochizuki, M., Shibuya‐Takahashi, R., Ota, K., Wakui, Y., Iwai, W., Kusaka, J., Saito, M., Suzuki, S., Sato, I., et al. (2025) · Cancers · doi:10.3390/cancers17122006 · Cited by 10
“In Japan, two mRNA vaccines, i.e., BNT162b2 (Pfizer-BioNTech, New York, NY, USA) and mRNA-1273 (Moderna, Cambridge, MA, USA), were approved in February and May 2021, respectively [29,30].”
Marchese, A. M., Kalkeri, R., Vadivale, M., Suntronwong, N., Toback, S. L., & Poovorawan, Y. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2232020 · Cited by 6
“The results of pivotal phase 3 trials demonstrated similar vaccine efficacy among mRNA vaccines BNT-162b2 and mRNA1273, and protein-based NVX-CoV2373 [29,46,47].”
Thompson, K., Shah, A. G., Grunbaum, A., & Oyesanmi, O. (2022) · Cureus · doi:10.7759/cureus.22685 · Cited by 6
“illustrates that the vaccine provides 95% efficacy when preventing COVID-19 symptoms at least seven days after the second dose [13].”
BackgroundEditorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.932915 · Cited by 9
Explaining the unexpected COVID-19 trends and potential impact across Africa.
Oduro‐Mensah, D., Oduro‐Mensah, E., Quashie, P. K., Awandare, G. A., & Okine, L. K. N. (2021) · F1000Research · doi:10.12688/f1000research.74363.1 · Cited by 8
Koskan, A. M., Larkey, L., Todd, M. W., & Kim, S. W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0299787 · Cited by 8
Cosma, C., Galla, L., Padoan, A., Furlan, G., Marchioro, L., Zaninotto, M., Basso, D., & Plebani, M. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0129 · Cited by 6
Liao, S., Hung, C., Chen, C., Yen, J.-Y., Hsu, C.-Y., Yen, A. M.-F., & Chen, C. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.04.026 · Cited by 6
Ahmed‐Belkacem, A., Redjoul, R., Brillet, R., Ahnou, N., Leclerc, M., Molina, D. S. L., Soulier, A., Gourgeon, A., Rodriguez, C., Maury, S., et al. (2022) · Viruses · doi:10.3390/v14091928 · Cited by 7
“COVID-19 RNA vaccines prevent infection in the majority of vaccine recipients.”
MethodInfluentialDelta variant: Partially sensitive to vaccination, but still worth global attention
Zhang, M., He, Y.-C., & Jie, Z. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0026 · Cited by 6
“232 JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE / JUL-SEP 2022 / VOL 10 / ISSUE 3 alpha variant, is the vaccine still protective? To date, many vaccines have been introduced, such as BNT162B2[52,53] and Chadox1,[54,55] and many biotechnology companies are manufacturing these vaccines.”
BackgroundInfluentialTobudic, S., Simader, E., Deimel, T., Straub, J., Kartnig, F., Heinz, L. X., Mandl, P., Haslacher, H., Perkmann, T., Schneider, L., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1049157 · Cited by 6
Azevedo‐Silva, J., Amorim, M., Tavares‐Valente, D., Sousa, P., Mohamath, R., Voigt, E. A., Guderian, J. A., Kinsey, R., Viana, S., Reis, F., et al. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114538 · Cited by 6
The general public’s intent to receive a COVID-19 vaccine in Saudi Arabia
Almoayad, F. A., Amer, L. B., Althubyani, N. T., Alajmi, S. M., Alshammari, A. A., & Alsuwayal, R. A. (2022) · International Journal of Health Promotion and Education · doi:10.1080/14635240.2022.2047094 · Cited by 7
“In particular, the BNT162b2 mRNA COVID-19 vaccine, which achieved 95% efficacy (Polack et al. 2020), was approved for use in Saudi Arabia (SA).”
COVID-19, a tale of two peaks: patients’ characteristics, treatments, and clinical outcomes
Banai, A., Taieb, P., Furie, N., Hochstadt, A., Merdler, I., Sapir, O. P. R., Granot, Y. N., Lupu, L., Ghantous, E., Borohovitz, A., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02711-1 · Cited by 6
Tamming, L. A., Duque, D., Bavananthasivam, J., Tran, A., Lansdell, C., Frahm, G. E., Wu, J., Fekete, E. E. F., Creskey, M., Raman, S. N. T., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101325 · Cited by 7
Kasai, H., Saito, G., Ito, S., Kuriyama, A., Kawame, C., Shikino, K., Takeda, K., Yahaba, M., Taniguchi, T., Igari, H., et al. (2022) · BMC Medical Education · doi:10.1186/s12909-022-03525-1 · Cited by 8
“These examples emphasized the difficulty of properly handling medical information from any standpoint and revealed the process of medical validation using several drugs/vaccines [18].”
BackgroundCOVID-19 Vaccine Prioritisation in Japan and South KoreaPreprint
Chun, J. Y., Jeong, H., Beutels, P., Ohmagari, N., Kim, Y., & Tsuzuki, S. (2021) · medRxiv · doi:10.1101/2021.04.16.21255649 · Cited by 6
A modular vaccine platform for optimized lipid nanoparticle mRNA immunogenicity
Fang, Z., Monteiro, V. S., Oh, C., Janabi, K. A., Romero, L., Ahsan, N., Yang, L., Peng, L., DiMaio, D., Lucas, C. G. D. O., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01478-6 · Cited by 7
“Of note, the SARS-CoV-2 spike protein, successfully targeted by the first Food and Drug Administration-approved LNP mRNA vaccines 22,23 , served as a benchmark antigen that is known to induce high antibody titres.”
Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells
Trines, M. M., Hoorn, D., Hofstraat, S. R. J., Zwolsman, R. C., Anbergen, T., Versteeg, I., van Elsas, Y., Deckers, J., Hendrikx, M., Kleuskens, T., et al. (2025) · Advanced Materials · doi:10.1002/adma.202504830 · Cited by 11
Chen, C., Fu, F., Ding, L., & Xiao, J. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13767 · Cited by 8
“During clinical trials, otologic symptoms such as hearing loss were not listed as common potential AEFIs for COVID-19 vaccine.(27,28) Due to the known limitations of clinical trials to detect particularly rare”
BackgroundThird booster vaccination and stopping the Omicron, a new variant of concern
Ghazvini, K., Karbalaei, M., & Keikha, M. (2022) · Vacunas (English Edition) · doi:10.1016/j.vacun.2022.05.005 · Cited by 7
“As many as 511 Omicron genome sequences have been recorded till February 17, 2022, 1,362, mostly being from UK, USA, Denmark, Germany and Canada.”
InfluentialEvaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens
Snoeck, J., Chiers, K., Tam, Y. K., Sanders, N. N., & Garmyn, A. (2023) · Poultry Science · doi:10.1016/j.psj.2023.103078 · Cited by 9
Fahrbach, K. R., Cichewicz, A. B., Chu, H., Fusco, M. D., Burnett, H. F., Volkman, H. R., Akin‐Fajiye, M., Mendoza, C. F., & Cappelleri, J. C. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2505754 · Cited by 7
Ong, M. J. Y., Khoo, C. S., Lee, Y. X., Poongkuntran, V., Tang, C. K., Choong, Y. J., Hod, R., & Tan, H. J. (2022) · Epilepsia Open · doi:10.1002/epi4.12658 · Cited by 6
“23 Interestingly, our study reported that PWE with normal BMI had a higher risk of developing both local and systemic AEFI compared to those underweight and obese PWE.”
Direct Single-Molecule Detection of mRNA–LNP Drugs in Blood
Furukawa, R., Shinoda, H., Tozaki, T., Makino, A., Yoshimura, M., Iida, T., Kawate, K., Kikuchi, M., Ishige, T., Takahashi, Y., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05862 · Cited by 8
Okuno, S., Higo, S., Kondo, T., Shiba, M., Kameda, S., Inoue, H., Tabata, T., Ogawa, S., Morishita, Y., Sun, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48084-7 · Cited by 6
Microbiome-Derived Lipid Nanoparticles for Improved Immunogenicity of mRNA Vaccines
Yong, S., Park, O. H., & Cho, S. (2024) · ACS Materials Letters · doi:10.1021/acsmaterialslett.3c01642 · Cited by 7
The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of COVID-19 Disease
Alkhafaji, D. M., Argan, R. J. A., AlBahrani, S., Alwaheed, A. J., Alqatari, S. G., Elq, A. A. A., Albaker, W., Alwazzeh, M., AlSulaiman, A., AlSulaiman, R., et al. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s365179 · Cited by 4
Kozak, K. E., Ouyang, L., Derkach, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01457-1 · Cited by 6
“No patients studied had a clinical history of Covid-19 infection.”
BackgroundInfluentialMeasuring vaccination coverage and concerns of vaccine holdouts from web search logs
Chang, S. Y., Fourney, A., & Horvitz, E. (2024) · Nature Communications · doi:10.1038/s41467-024-50614-4 · Cited by 12
“In our setting, we set t = max(tmed, tprec), since we required new vaccine intent URLs to score above these two thresholds (in at least 6 out of 10 trials): (1) tmed, the median score of positive URLs in the test set and (2) tprec, the minimum threshold required to achieve precision of at least 0.”
BackgroundMethodInfluentialTransient cryoglobulinaemic vasculitis following ChAdOx1 nCoV-19 vaccine
Ahmer, S., Bourke, J., & Ardakani, N. M. (2022) · BMJ Case Reports · doi:10.1136/bcr-2022-250913 · Cited by 6
Pandey, A. K., & Verma, S. (2022) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2022.2137196 · Cited by 6
“Though the newly developed vaccines have reduced the rate of increase in cases, the associated limitation of allergic reactions by PEG encapsulation and the development of mutant SARS-CoV-2 omicron strain demand further improvement and validations [3,10,11].”
BackgroundMethodEffectiveness of mRNA COVID-19 Vaccines among Employees in an American Healthcare SystemPreprint
Shrestha, N. K. M., Nowacki, A. S., Burke, P. C., Terpeluk, P., & Gordon, S. M. (2021) · medRxiv · doi:10.1101/2021.06.02.21258231 · Cited by 6
“This study found that the mRNA SARS-CoV-2 vaccines were 97.1% effective in protecting against SARS-CoV-2 infection, an effectiveness that was similar to vaccine efficacy noted in previously published clinical trials [1,2], and in large vaccine effectiveness studies in Israel [3,4].”
BackgroundResultInfluentialThe prevention and treatment of COVID-19 in patients treated with hemodialysis
Zeng, B., Zhou, J., Peng, D., Dong, C., & Qin, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01389-9 · Cited by 9
“However, the protection rate was still low compared to the general population [74, 76].”
BackgroundInfluentialGan, M., Cao, J., Zhang, Y., Fu, H., Lin, X., Ouyang, Q., Xu, X., Yuan, Y., & Fan, X. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29452 · Cited by 6
“32 – 34 In fact, the newly circulating viral variant is not fully capable of SARS ‐ CoV ‐ 2 Beta, Delta, and Omicron strains might induce a broader T cell cross ‐ reactivity.”
BackgroundThe Application of mRNA Technology for Vaccine Production—Current State of Knowledge
Paczkowska, A., Hoffmann, K., Andrzejczak, A., Pucek, W. F., Kopciuch, D., Bryl, W., Nowakowska, E., & Kus, K. (2025) · Vaccines · doi:10.3390/vaccines13040389 · Cited by 12
“BNT162b2 (Comirnaty) must be stored at − 60 ◦ C for up to 6 months; 2–8 ◦ C for up to 5 days, while mRNA-1273 (Moderna) can be stored at − 15 ◦ C or lower for up to 6 months; 4–8 ◦ C for up to a month and at room temperature for up to 12 h [13,14].”
Sakers, S. H., Fiduccia, G., Byrne, K. E., Reddy, B. P. K., Dahlman, J. E., & Prausnitz, M. R. (2025) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2025.114819 · Cited by 6
Considerations in Understanding Vaccine Effectiveness
Lau, C. S., & Aw, T. C. (2022) · Vaccines · doi:10.3390/vaccines11010020 · Cited by 7
“For example, the prevalence of COVID-19 in the BNT162b2 study [33] is calculated as 0.”
BackgroundMethodInfluentialAdjobimey, T., Meyer, J., Sollberg, L., Bawolt, M., Berens, C., Kovačević, P., Trudić, A., Parčina, M., & Hoerauf, A. M. (2021) · Research Square · doi:10.21203/rs.3.rs-1197023/v1 · Cited by 6
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
Yang, I.-N., Lu, C.-L., Tang, H.-J., Kuo, Y.-C., Tsai, L.-H., Tu, K.-C., Wang, J.-J., & Chien, C.-C. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273676 · Cited by 7
Vaccination shapes evolutionary trajectories of SARS-CoV-2Preprint
Meijers, M., Ruchnewitz, D., Łuksza, M., & Lässig, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.19.500637 · Cited by 6
Erdoğan, M. A., Gürbüz, O., Bozkurt, M. F., & Erbaş, O. (2024) · Neurochemical Research · doi:10.1007/s11064-023-04089-2 · Cited by 9
RetractedButler, M., Coebergh, J. A., Safavi, F., Carson, A. J., Hallett, M., Michael, B. D., Pollak, T. A., Solomon, T., Stone, J., & Nicholson, T. R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3868756 · Cited by 6
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain
Pardo‐Seco, J., Mallah, N., López‐Pérez, L., González-Pérez, J. M., Rosón, B., Otero‐Barrós, M., Durán‐Parrondo, C., Rodríguez-Tenreiro, C., Calle, I. R., Gómez‐Carballa, A., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074039 · Cited by 6
“Though clinical trials had been already carried out to measure the short-term efficacy of this vaccine prior to its approval [3], observational studies are required to determine vaccine effectiveness (VE) in diverse populations and real-world settings [4].”
BackgroundNovel bionic inspired nanosystem construction for precise delivery of mRNA
Yang, T., Xia, L., Li, G., Zhao, J., Li, J., Ge, J., Yuan, Q., Zhang, J., He, K., & Xia, Q. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1160509 · Cited by 10
“Among these, two have been authorized and successfully applied in the clinic for the delivery of mRNA-based COVID-19 vaccines, mRNA-1273 and BNT162b21 (Anderson et al., 2020; Polack et al., 2020; Baden et al., 2021).”
BackgroundRNA‐Based Therapeutics: Cutting‐Edge Advances in Clinical Research
Ferreira, D., & Rodrigues, L. R. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500082 · Cited by 7
Elhassan, M., Ahmad, H., Mohamed, M., Saidahmed, O., & Elhassan, A. E. E. (2021) · Cureus · doi:10.7759/cureus.18805 · Cited by 7
“Since the end of 2020 and the beginning of 2021, several vaccines have been found promising in terms of efficacy and safety [5-7].”
BackgroundHollinghurst, J., North, L., Perry, M., Akbari, A., Gravenor, M. B., Lyons, R. A., & Fry, R. J. (2021) · Age and Ageing · doi:10.1093/ageing/afab223 · Cited by 7
“Similarly, the initial Pfizer BioNTECH trials included only 774 individuals aged 75 or over and 3,848 individuals aged 65 and over from a total of 18,198 vaccinated individuals [5].”
BackgroundDen Patienten wirklich verstehen lernen: Real-world-Evidenz aus der „patient journey“
Zyumbileva, P., Uebe, M., Rudolph, S., & Kalle, C. V. (2022) · Prävention und Gesundheitsförderung · doi:10.1007/s11553-022-00984-8 · Cited by 8
Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19
Hall, K., MFONE, F., Shallcross, M., & Pathak, V. (2021) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2021.20384 · Cited by 6
Ucciferri, C., Auricchio, A., Vecchiet, J., & Falasca, K. (2022) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2022.023 · Cited by 8
Kaznadzey, A., Tutukina, M. N., Bessonova, T. A., Kireeva, M. L., & Mazo, I. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.797918 · Cited by 6
A Short Series of Case Reports of COVID-19 in Immunocompromised Patients
Mishra, M., Zahra, A., Chauhan, L. V., Thakkar, R., Ng, J., Joshi, S., Spitzer, E. D., Marcos, L. A., Lipkin, W. I., & Mishra, N. (2022) · Viruses · doi:10.3390/v14050934 · Cited by 6
“This likely represents the use of prototype SARS-CoV-2 sequences for vaccine design [45,46].”
MethodImmunogenicity and safety of SARS-CoV-2 vaccines in clinical trials
Lim, H. Y., Arip, M., Yahaya, A. A. A.-F. B., Jazayeri, S. D., Poppema, S., & Poh, C. L. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5024 · Cited by 7
Recent developments of vaccines for older adults: Adjuvants and beyond
Pangrazzi, L., & Weinberger, B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2517931 · Cited by 12
COVID-19 Pneumonia Complicated by Seizure Due to Severe Hyponatremia
Habib, M. B., Hamad, M. K., Kalash, T., et al. (2021) · Cureus · doi:10.7759/cureus.15603 · Cited by 6
“6% after receiving one and two doses, respectively [3].”
BackgroundPemphigus foliaceous after mRNA COVID-19 vaccine
Reis, J., Nogueira, M., Figueiras, O., Coelho, A., Velho, G., & Raposo, I. (2022) · European Journal of Dermatology · doi:10.1684/ejd.2022.4294 · Cited by 6
“BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes prefusion stabilized, membraneanchored SARS-CoV-2 full-length spike protein [8].”
BackgroundEsmaeilzadeh, A., Hadiloo, K., Yaghoubi, S., Makoui, M. H., & Mostanadi, P. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01056-7 · Cited by 8
“These vaccines use mRNA enclosed in LNPs, which protect the fragile mRNAs, extend their sta - bility, and enhance the delivery of the genetic material into target cells [ 60].”
Chen, J., Wang, Q., Jiang, N., Zhang, Y., Wang, T., Cao, H., Liu, Y., Yang, Y., & Wang, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-53806-6 · Cited by 7
Exploration and Ethical Analysis of Open-label Pediatric Vaccine Trials in a Pandemic
Wolfe, I. D., Patel, A., Kociolek, L. K., Fazal, A., Jhaveri, R. R., & Lantos, J. D. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.04.010 · Cited by 6
Sendo, F., Yoshitake, H., & Araki, Y. (2022) · Microbiology and Immunology · doi:10.1111/1348-0421.12978 · Cited by 5
Chammartin, F., Griessbach, A., Kusejko, K., Audigé, A., Epp, S., Stoeckle, M. P., Eichenberger, A. L., Amstutz, A., Schönenberger, C., Hasse, B. K., et al. (2023) · AIDS · doi:10.1097/qad.0000000000003751 · Cited by 7
Haider, T., Ali, J., Ali, S. M., Iftikhar, A., Siddiqui, A. A., Khan, A. S., Qamar, J. A., Sohail, K., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.46543 · Cited by 5
“These results were consistent with those of another randomized control study that noticed a decreased prevalence of serious adverse events and described comparable side effects [25].”
ResultIncreasing vaccine supply with low dead-volume syringes and needles
Daré, B. L., Bacle, A., Lhermitte, R., et al. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121053 · Cited by 6
Cserep, G., Morrow, D. A., Latchford, K., et al. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-021-02118-4 · Cited by 6
“A two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in persons 16 years of age or older, whereas safety over a median of 2 months was similar to that of other viral vaccines [5].”
Aguinam, E. T., Nadesalingam, A., Chan, A. C. Y., Smith, P., Paloniemi, M., Cantoni, D. M., Gronlund, J., Gronlund, H., Carnell, G., Castillo‐Olivares, J., et al. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100091 · Cited by 8
Heil, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259879 · Cited by 12
Prognostic markers for the clinical course in the blood of patients with SARS-CoV-2 infection
Fischer, J., Balz, V., Jazmati, D., Bölke, E., Freise, N. F., Keitel, V., Feldt, T., Jensen, B. O., Bode, J. G., Lüdde, T., et al. (2022) · European journal of medical research · doi:10.1186/s40001-022-00864-z · Cited by 7
“SARS-CoV-2 continuously mutates and poses a significant challenge to cellular and humoral immunity and vaccination [1, 6].”
BackgroundYoo, S., Han, E. L., Murray, A. M., Kim, D., Bang, E., & Mitchell, M. J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03793 · Cited by 8
Pityriasis rubra pilaris nach COVID-19-Impfung: Kausaler Zusammenhang oder Koinzidenz?
Bramhoff, A. C., Wesselmann, U., Bender, S. T., et al. (2022) · Die Dermatologie · doi:10.1007/s00105-022-04972-z · Cited by 6
Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
Holm-Yildiz, S. D., Dysgaard, T., Krag, T. O. B., Pedersen, B. S., Hamm, S. R., Pérez‐Alós, L., Hansen, C. B., Pries‐Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., et al. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578215 · Cited by 7
Zagouri, F., Papatheodoridi, A. M., Liontos, M., Briasoulis, Α., Sklirou, A. D., Skafida, E., Fiste, O., Markellos, C., Andrikopoulou, Α., Koutsoukos, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10091474 · Cited by 6
Tada, R., Honjo, E., Muto, S., Takayama, N., Kiyono, H., Kunisawa, J., & Negishi, Y. (2022) · Membranes · doi:10.3390/membranes12060635 · Cited by 6
“Recent advances in science and technology have led to the launch of a series of next-generation vaccines, including two RNA vaccines [3,4], one viral vector vaccine [5], and one DNA vaccine [6].”
BackgroundValles, T. E., Shoenhard, H., Zinski, J. M., Trick, S., Porter, M. A., & Lindstrom, M. R. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010042 · Cited by 7
Update zu: Neurologische Manifestationen bei COVID-19
Berlit, P. (2022) · DGNeurologie · doi:10.1007/s42451-022-00429-8 · Cited by 4
“Zum jetzigen Zeitpunkt (8/2021) sind in Deutschland und der EU 4 Impfstoffe zugelassen: 2 basierend auf mRNA-Technologie, Comirnaty® von BioNTech [42] und Spikevax® von Moderna Biotech [43], und 2 basierend auf Adenovirusvektortechnologie, Vaxzevria® von AstraZeneca [44, 45] und COVID-19 Vaccine Janssen® von Janssen-C…”
BackgroundInfluentialUnilateral lymphadenopathy associated with COVID‐19 vaccination
Kado, S., Kamiya, K., Iwabuchi, S., et al. (2021) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12217 · Cited by 6
Míguez, H. M., García, I. M., Gómez, M. O., Merino, I. M. G., Cano, E. L., & de la Torre, A. (2023) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2023.02.009 · Cited by 6
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19Preprint
Hardt, K., Vandebosch, A., Sadoff, J., et al. (2022) · medRxiv · doi:10.1101/2022.01.28.22270043 · Cited by 6
Hamid, R., Korkmazer, B., Kızılkılıç, E. K., Arman, G. M., Özoğul, M., Kargın, O. A., Arslan, S., & Kızılkılıç, O. (2022) · Ear Nose & Throat Journal · doi:10.1177/01455613221113818 · Cited by 6
Erythema nodosum after COVID-19 vaccine
Maranini, B., Ciancìo, G., Corazza, M., Ruffilli, F., Galoppini, G., & Govoni, M. (2022) · Reumatismo · doi:10.4081/reumatismo.2022.1475 · Cited by 6
Ponce, P., Peralta, R., Felix, C., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191610091 · Cited by 6
“However, CKD-5D patients were not included in the clinical trials, thus there are no data on the efficacy for this group of patients [10,11].”
BackgroundGuerstein, S., Romeo-Aznar, V., Dekel, M., et al. (2020) · medRxiv · doi:10.1101/2020.12.22.20248622 · Cited by 6
Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center
Brunello, A., Guarneri, V., Coppola, M., Bernardi, M., Ottolitri, K., Ghi, M. G., Mioranza, E., Vianello, F., Gottardi, M., Lonardi, S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab037 · Cited by 6
Monitoring the COVID-19 immune landscape in Japan
Sasanami, M., Kayano, T., & Nishiura, H. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.005 · Cited by 9
Kridin, K., Schonmann, Y., Onn, E., Bitan, D. T., Weinstein, O., & Cohen, A. D. (2022) · American Journal of Clinical Dermatology · doi:10.1007/s40257-022-00672-5 · Cited by 6
Ott, A. C., Loll, P. J., & Burns, J. M. (2025) · Vaccines · doi:10.3390/vaccines13070702 · Cited by 8
“The Spike-targeted mRNA/LNP vaccines for SARS-CoV-2 demonstrated safety, immunogenicity, and efficacy in adults, adolescents, young children, and infants [17,51–54].”
Serrano, L., Algarate, S., Herrero‐Cortina, B., Bueno, J., González-Barriga, M. T., Ducons, M., Montero‐Marco, J., Acha, B., Taboada, A., Sanz-Burillo, P., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15699 · Cited by 4
“Pfizer vaccine confers 95% protection against COVID- 19 (Polack et al., 2020).”
BackgroundUse of COVID-19 vaccines in patients with liver disease and post-liver transplantation
Alqahtani, S. A., Barry, M. A., Memish, Z. A., Hashim, A. H., Fares, M. A. A., Alghamdi, S. A., Al-hamoudi, W., Al‐Judaibi, B., Alhazzani, W. A., Al‐Tawfiq, J. A., et al. (2021) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_223_21 · Cited by 6
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.